No Data
No Data
ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment
iTeos Therapeutics (ITOS) said Monday it has dosed the first patient in its phase 3 trial of belrestotug with dostarlimab, triggering a $35 million development milestone payment from its belrestotug p
ITeos Therapeutics Has Dosed First Patient In GALAXIES Lung-301 Phase 3 Trial Of Belrestotug+Dostarlimab Vs. Placebo+Pembrolizumab For First-line Advanced, Unresectable, Or Metastatic PD-L1 High Non-Small Cell Lung Cancer
This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug.iTeos and GSK entered into an exclusive development and commercialization collaboration in
GSK Says First Single-Dose Medicine To Prevent Relapse Of P. Vivax Malaria Launched In Thailand And Brazil
GSK Says First Single-Dose Medicine To Prevent Relapse Of P. Vivax Malaria Launched In Thailand And Brazil
What the U.K. Election Means for Oil Stocks and Other Sectors -- Barrons.com
By Brian Swint U.K. voters gave the biggest election victory to the Labour Party since former Prime Minister Tony Blair's landslide win in 1997. If history is anything to go by, that could be a boon
'FDA to Evaluate Potential Risk of Neural Tube Birth Defects With HIV Medicine Dolutegravir (Juluca, Tivicay, Triumeq)' - FDA
'FDA to Evaluate Potential Risk of Neural Tube Birth Defects With HIV Medicine Dolutegravir (Juluca, Tivicay, Triumeq)' - FDA
GSK's RSV Vaccine Sales Outlook Dims After CDC's Narrowed Recommendation -- Market Talk
0619 GMT - GSK's sales outlook for its respiratory syncytial virus vaccine, Arexvy, could take a blow after U.S. health officials narrowed their age recommendation for RSV shots last week, Citi analys